Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol

BACKGROUND: Liraglutide is an injectable therapy to treat type 2 diabetes (T2DM), belonging to the glucagon-like peptide-1 receptor agonist class of drugs. The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial established that liraglutide demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinton, William, Feher, Michael, Munro, Neil, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984905/
https://www.ncbi.nlm.nih.gov/pubmed/29605893
http://dx.doi.org/10.1007/s13300-018-0390-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984905/
https://www.ncbi.nlm.nih.gov/pubmed/29605893
http://dx.doi.org/10.1007/s13300-018-0390-8

Ejemplares similares